Effect of Varenicline on Cognitive Function in Cigarette Smokers With Schizophrenia.

Trial Profile

Effect of Varenicline on Cognitive Function in Cigarette Smokers With Schizophrenia.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Sep 2016

At a glance

  • Drugs Varenicline (Primary)
  • Indications Schizoaffective disorder; Schizophrenia; Smoking withdrawal
  • Focus Pharmacodynamics
  • Most Recent Events

    • 25 Aug 2016 Status changed from active, no longer recruiting to completed.
    • 24 Feb 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 17 Mar 2014 Planned End Date changed from 1 Jun 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top